Pay in 4 interest-free payments of $5.54 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Generation I Semaglutide GLP-1 only Peak Weight Loss 14.9% STEP 1 trial 68 weeks Receptor Coverage Single GLP-1 FDA Status Approved (Wegovy, 2021) FIRST PUBLISHED Wilding et al., NEJM 2021 Generation II Tirzepatide GLP-1 + GIP Peak Weight Loss 22.5% SURMOUNT-1 trial 72 weeks Receptor Coverage Dual GLP-1, GIP FDA Status Approved (Zepbound, 2023) First Published Jastreboff et al., NEJM 2022 Generation III Retatrutide GLP-1 + GIP + GCGR Peak Weight Loss 24.2% Phase 2 48 weeks (highest dose) Receptor Coverage Triple GLP-1, GIP, GCGR FDA Status Phase 3 (TRIUMPH program) First Published Jastreboff et al., NEJM 2023 -SELECTED LITERATURE Key Retatrutide research and clinical publications
10.1016/j.brainres.2024.149263 73 SunM.LiY.LiuM.LiQ.ShiL.RuanX.et al (2023)
Extended productive working hours
Description Features Reviews
In a double blinded, placebo-controlled trial, patients showed an average weight loss of 9.9% at 24 weeks on weekly pemvidutide (2.4mg) over placebo
This isnt unusual
US$ 24.75
US$ 20.88
US$ 21.79
US$ 26.51
US$ 26.56
